ProprietaryDrugDevelopmentandMarketingAgreement专利药品研发及销售协议doc文档格式.docx

ProprietaryDrugDevelopmentandMarketingAgreement专利药品研发及销售协议doc文档格式.docx

《ProprietaryDrugDevelopmentandMarketingAgreement专利药品研发及销售协议doc文档格式.docx》由会员分享，可在线阅读，更多相关《ProprietaryDrugDevelopmentandMarketingAgreement专利药品研发及销售协议doc文档格式.docx（18页珍藏版）》请在冰豆网上搜索。

ThisPROPRIETARYDRUGDEVELOPMENTANDMARKETINGAGREEMENT（Agreement）,effectiveon_________,_________,_________（M,D,Y）（theEffectiveDate）,ismadebyandbetweenAAA,Inc.,acorporationorganizedandexistingunderthelawsof_________andhavingitsprincipalofficesat_________（hereinafterAAA）,andBBBCompany（hereinafterBBB）,ageneralpartnershiporganizedandexistingunderthelawsoftheStateof_________andhavingitsprincipalofficesat_________.

WHEREAS,BBBisinthebusinessofdiscovering,developing,manufacturingandmarketingnewchemicalentitiesaspharmaceuticalproducts;

WHEREAS,AAAisinthebusinessofdeveloping,manufacturingandmarketinggenericandproprietarydrugs,andinparticularisdevelopingCyPat（TM）,Seasonale（TM）and***asproprietarydrugs;

WHEREAS,thePartieshavedeterminedthatcertainproprietarydrugsunderdevelopmentatAAAmaybemoreefficientlyandeffectivelydevelopedandmarketedthroughabeneficialcollaboration,andinparticular,thatcollaborativedevelopmentandmarketingofCyPat（TM）,Seasonale（TM）and***wouldbebeneficialtothePartiesandtheirpatients;

WHEREAS,BBBisnotinthepositiontodevelopCyPat（TM）,Seasonale（TM）and***itselfandbelievesthatcollaborativedevelopmentCyPat（TM）,Seasonale（TM）and***wouldbebeneficialtotheParties;

and

WHEREAS,thePartieswishtocreateanalliancethatpermitssuchefficientandeffectivedevelopmentandmarketing.

NOW,THEREFORE,inconsiderationofthemutualpromiseshereinaftersetforth,andintendingtobelegallyboundhereby,AAAandBBBherebyagreeasfollows:

1.Definitions.

EachofthecapitalizedtermsusedinthisAgreement（otherthantheheadingsoftheSections）shallhavethemeaningindicatedinthisAgreement.

1.1ThetermAffiliateorAffiliatedshallmean,withrespecttoaParty,anyotherbusinessentitywhichdirectlyorindirectlycontrols,iscontrolledby,orisundercommoncontrolwith,suchParty.AsusedinthisdefinitionofAffiliate,thetermcontrolshallmeandirectorindirectbeneficialownershipofmorethanfiftypercent（50%）ofthevotingorincomeinterestinsuchbusinessentity.

1.2ThetermAffiliatedCustomershallmean,withrespecttoaParty,anyAffiliate.

1.3ThetermAgencyasusedhereinmeansanygovernmentalregulatoryauthorityresponsibleforgrantinghealthorpricingapprovals,registrations,importpermits,andotherapprovalsrequiredbeforeaFundedProductmaybetestedormarketedinanycountry.ThetermAgencyincludestheFoodandDrugAdministration（FDA）.

1.4ThetermAgencyApprovalshallmeanfinalauthorizationbyanAgencytomarketandselltheFundedProductsinacountryintheTerritory.

1.5ThetermCommerciallyReasonableEffortsasusedhereinshallmeanthoseeffortsconsistentwiththeexerciseofprudentscientificandbusinessjudgmentasappliedtootherresearch,developmentandcommercializationeffortsforproductsofsimilarscientificandcommercialpotentialwithintheresearchprogramsandrelevantproductlinesofsuchParty.

1.6ThetermCyPat（TM）asusedhereinmeanscyproteroneacetate,asyntheticoralhydroxyprogesteroneagentusedinthetreatmentofprostatecanceranditsassociatedsyndromes.

1.7ThetermDevelopmentCostsasusedhereinmeansExternalVerifiableDevelopmentExpenseandInternalVerifiableDevelopmentExpense.

1.8Theterm***asusedhereinmeans******.

1.9ThetermExternalVerifiableDevelopmentExpenseasusedhereinincludesthoseexternalcoststoacquire,developandsubmittheFundedProductstotheFDAforapprovalandreportedasresearchanddevelopmentexpenseonfinancialstatementstoshareholdersandconsistentwithFinancialAccountingStatementNo.2.Suchcostsinclude,butarenotlimitedto,theexpensesincludedinAttachmentAhereto.

1.10ThetermFirstCommercialSaleshallmean,withrespecttotheFundedProducts,thefirstsaleforuseorconsumptionbythepublicofsuchFundedProductsintheTerritoryafterallrequiredapprovals,includingmarketingapproval,havebeengrantedbytheFDA.

1.11ThetermFundedProductsasusedhereinmeansAAA’sproprietarydevelopmentcandidatesCyPat（TM）,Seasonale（TM）,***andanyproprietarydrugsubstitutedpursuanttoSection2.9hereof.ThetermFundedProductreferstoanyoneoftheprecedingdevelopmentcandidatesinthesingular.

1.12ThetermInternalVerifiableDevelopmentExpensesasusedhereinmeansthoseinternalcoststodevelopandsubmittheFundedProductstotheFDAforapprovalandreportedasresearchanddevelopmentexpenseonfinancialstatementstoshareholdersandconsistentwithFinancialAccountingStatementNo.2.Suchcostsinclude,butarenotlimitedto,thee